Kwayar cutar sankarar bargo da FDA ta amince da ita azaman nasara

Share Wannan Wallafa

FDA ya ba da nasarar maganin sa quzartinib a nasara nasara. Quizartinib ne mai FLT3 inhibitor karkashin bincike don kula da manya marasa lafiya tare da koma baya refractory Saukewa: FLT3-ITD myeloid cutar sankarar bargo ( AML ). Wannan ganewa zai hanzarta ci gaban tambaya kuma ana sa ran kawo sabbin magunguna ga marasa lafiya da wuri-wuri.

AML m blood and bone marrow cancer that causes dysfunctional cancerous leukocytes to proliferate and accumulate uncontrollably, and affects the production of normal blood cells. The United States this year is expected to have more than 19000 sunan sababbin marasa lafiya da aka gano, kuma fiye da 10000 Ge AML mutuwar. A 2005-2011 Sakamakon binciken ya nuna cewa 5- shekara ta rayuwa kudi na AML marasa lafiya ne kawai 26% , wanda shine mafi ƙasƙanci a cikin kowane nau'in cutar sankarar bargo. FLT3 maye gurbin kwayoyin halitta shine mafi yawan maye gurbi a cikin AML marasa lafiya, yayin da Saukewa: FLT3-ITD shine mafi saurin maye gurbi na FLT3 kwayar halitta, kuma kusan kashi ɗaya cikin huɗu na AML marasa lafiya suna dauke da wannan maye gurbi. Idan aka kwatanta da marasa lafiya waɗanda ba su ɗaukar wannan maye gurbi, marasa lafiya da Saukewa: FLT3-ITD maye gurbi yana da mummunan hasashen, haɗarin sake dawowa da cutar kansa, da haɗarin mutuwa bayan sake dawowa. Ko da waɗannan marasa lafiya sun sami dashen kwayar cutar hematopoietic ( HSCT ), damar sake kamuwa da cutar kansa bayan jiyya har yanzu ya fi na marasa lafiyar da basa dauke wannan maye gurbi. A halin yanzu, babu wani magani da aka yarda da shi don wannan cutar. Sabili da haka, wannan nasarar nasara ana sa ran kawo sabon bege ga marasa lafiya Saukewa: FLT3-ITD .

Baya ga ganewar nasarar farfadowa, tambaya kuma samu FDA cancantar gaggawa don sake dawowa refractory AML magani , da kuma cancantar magungunan marayu AML bayar da FDA da Hukumar Kula da Magunguna ta Turai ( Ema ). Quizartinib shine har yanzu a cikin matakan bincike da ci gaba kuma ba a yarda da shi a kowace ƙasa ba. Ba a tabbatar da tsaro da haƙuri har yanzu ba. Koyaya, ana sa ran wannan yardar don hanzarta haɓaka maganin, wanda shine kyakkyawan labari ga marasa lafiya.

Biyan kuɗi zuwa ga Newsletter

Sami sabuntawa kuma kada ku rasa bulogi daga Cancerfax

Toarin Don Bincika

Human-Based CAR T Cell Therapy: Breakthroughs And Challenges
CAR T-Cell far

Human-Based CAR T Cell Therapy: Breakthroughs and Challenges

Human-based CAR T-cell therapy revolutionizes cancer treatment by genetically modifying a patient’s own immune cells to target and destroy cancer cells. By harnessing the power of the body’s immune system, these therapies offer potent and personalized treatments with the potential for long-lasting remission in various types of cancer.

Fahimtar Ciwon Sakin Cytokine: Dalilai, Alamu, da Jiyya
CAR T-Cell far

Fahimtar Ciwon Sakin Cytokine: Dalilai, Alamu, da Jiyya

Ciwon Saki na Cytokine (CRS) wani tsarin rigakafi ne wanda sau da yawa ke haifar da wasu jiyya kamar immunotherapy ko CAR-T cell far. Ya ƙunshi yawan sakin cytokines, yana haifar da alamun bayyanar da ke fitowa daga zazzabi da gajiya zuwa rikice-rikice masu haɗari masu haɗari kamar lalacewar gabbai. Gudanarwa yana buƙatar kulawa da hankali da dabarun shiga tsakani.

Ana buƙatar taimako? Ourungiyarmu a shirye take don taimaka muku.

Muna fatan samun lafiya cikin sauri na masoyinku da na kusa.

Fara hira
Muna Kan layi! Yi Taɗi da Mu!
Duba lambar
Hello,

Barka da zuwa CancerFax!

CancerFax wani dandali ne na majagaba wanda aka keɓe don haɗa mutane da ke fuskantar ciwon daji na zamani tare da hanyoyin kwantar da hankali kamar CAR T-Cell far, TIL far, da gwaji na asibiti a duk duniya.

Bari mu san abin da za mu iya yi muku.

1) Maganin ciwon daji a kasashen waje?
2) CAR T-Cell far
3) rigakafin cutar daji
4) Shawarar bidiyo ta kan layi
5) Maganin Proton